Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
Shares of Bellicum Pharmaceuticals BLCM lost 50.1% on Mar 15 after management announced that it has decided to discontinue the ongoing phase I/II studies evaluating its GoCAR-T cell product candidates in heavily pre-treated cancer patients. Consequently, the studies evaluating the candidates, BPX-60...